Disease Risk: Mapping the emerging burden of dengue

The first nationally-representative survey of dengue has revealed the growing burden of the disease in Bangladesh.
  1. Oliver Brady  Is a corresponding author
  1. London School of Hygiene & Tropical Medicine, United Kingdom

Dengue is a viral disease spread by mosquitoes and found in more than 120 countries around the world (Bhatt et al., 2013). Because the species that transmits the disease, Aedes aegypti, lives in dense man-made environments, recent urbanization throughout the tropical world has accelerated the spread of dengue (Bhatt et al., 2013). Aedes aegypti is also the primary vector for a number of other diseases, including Zika, chikungunya and Yellow Fever, so understanding how to control the global emergence of dengue could help to prevent the spread of these diseases.

However, getting accurate data on who is being infected is surprisingly difficult. Only a small proportion of people (11–32%) are likely to have symptoms after contracting dengue, with few being sick enough to require formal medical care (Bhatt et al., 2013; Undurraga et al., 2013). And even if they receive medical care, misdiagnosis and under-reporting are common. This means that maps based on clinical case counts are not always useful, and may just reflect differences in access to healthcare, diagnostics and ability to report cases.

The gold standard for measuring who has been infected with dengue is a seroprevalence survey, where serum (blood) samples are taken from a representative group of people and tested for antibodies against the dengue virus. Now, in eLife, Henrik Salje and colleagues (who are based at institutes in France, the United States and Bangladesh) report how they have used this approach, which is usually reserved for local studies, on a scale never seen before to provide new insights into the transmission of dengue at a national level in Bangladesh (Salje et al., 2019).

Salje et al. visited 70 randomly selected communities across Bangladesh, between 2014 and 2016. During these visits, randomly selected residents were asked to contribute a blood sample and to answer a range of questions about behaviours thought to increase or decrease the risk of dengue. Overall, they found that 24% of participants showed evidence of previous dengue infection: this was much lower than the figures in other affected regions, such as Indonesia (~70%), where dengue has been around much longer (Tam et al., 2018). They also found that males were more likely to be infected than females, and that regular travellers were almost twice as likely to be infected as people who did not travel regularly.

However, the biggest factor in determining the risk of infection was location: over 80% of individuals in big cities, such as Dhaka, had been infected with the virus at some stage in their life, whereas fewer than 5% of people in rural areas showed signs of any previous infection. Using the results of their survey, Salje et al. were able to construct models that could predict seroprevalence in areas where data had not been collected, and then use this information to produce an updated risk map for dengue across Bangladesh (Figure 1).

Mapping dengue risk in Bangladesh.

A cross-sectional seroprevalence map (right) of dengue risk in Bangladesh, based on data collected from 70 communities throughout the country (Salje et al., 2019), shows that the risk is highest in the cities of Chittagong (in the south east), Khulna (south west) and Dhaka (in the middle of the country). Previous maps, such as this map based on data from Bhatt et al. (2013) (left), have predicted more widespread risk throughout the country, but these maps were largely based on less detailed data and often relied on extrapolation from nearby countries. This new study by Sajle et al. may suggest that there are unique, as yet unknown, factors that constrain the current distribution of dengue in Bangladesh.

By comparing seroprevalence between different age groups, Salje et al. were able to estimate the rate at which infections accumulate. Using standard 'catalytic models' (and making some assumptions about how long dengue has been in Bangladesh) they estimated that about 2.4 million people, out of a population of ~160 million, are infected with dengue virus in Bangladesh each year. In contrast fewer than 6,000 dengue cases per year were reported over the same time period, mostly in Dhaka (Mutsuddy et al., 2019). The results from this survey have the potential to play an important role in expanding and adapting dengue surveillance practices in Bangladesh.

Salje et al. also suggest that the current distribution of mosquito species in Bangladesh may be the cause of the limited spread of dengue. The mosquito that carries dengue, Aedes aegypti, was found in higher abundance in urban areas, whilst Aedes albopictus, a mosquito species that carries and transmits the virus less effectively, was more common in rural areas.

Together, these results paint a picture of a country part way through the emergence of dengue. Transmission is already high in urban centres but – unlike many countries in South East Asia and Latin America – regular, continuous transmission has yet to spread to more rural areas. However, more work is needed to understand how human movement and lower transmission potential in rural areas interact in shaping the current distribution of dengue in Bangladesh (Wesolowski et al., 2015). Genetic analyses of circulating dengue viruses can be used to identify the origins of outbreaks (Salje et al., 2017), which could help with efforts to contain the spread of the virus.

By proving the feasibility and value of nationally-representative seroprevalence surveys for dengue, it is hoped that the results of Salje et al. will renew interest in mass disease surveillance for dengue. Such community-representative surveys have proven instrumental for targeting and evaluating interventions for successful malaria control (Bhatt et al., 2015). A range of new dengue vaccines are currently becoming available, but some of these will only be beneficial if targeted to the areas of highest transmission (Flasche et al., 2016). Therefore, having regularly updated maps that accurately show the national spread of dengue will be critical in the ongoing fight against further expansion of the disease.


Article and author information

Author details

  1. Oliver Brady

    Oliver Brady is in the Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom

    For correspondence
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3235-2129

Publication history

  1. Version of Record published: May 13, 2019 (version 1)


© 2019, Brady

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.


  • 2,883
    Page views
  • 266
  • 4

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Oliver Brady
Disease Risk: Mapping the emerging burden of dengue
eLife 8:e47458.

Further reading

    1. Epidemiology and Global Health
    Tina Bech Olesen, Henry Jensen ... Morten Rasmussen
    Research Article

    Background: Worldwide, most colorectal cancer screening programmes were paused at the start of the COVID-19 pandemic, whilst the Danish faecal immunochemical test (FIT)-based programme continued without pausing. We examined colorectal cancer screening participation and compliance with subsequent colonoscopy in Denmark throughout the pandemic.

    Methods: We used data from the Danish Colorectal Cancer Screening Database among individuals aged 50-74 years old invited to participate in colorectal cancer screening from 2018-2021 combined with population-wide registries. Using a generalised linear model, we estimated prevalence ratios (PR) and 95% confidence intervals (CI) of colorectal cancer screening participation within 90 days since invitation and compliance with colonoscopy within 60 days since a positive FIT test during the pandemic in comparison with the previous years adjusting for age, month and year of invitation.

    Results: Altogether, 3,133,947 invitations were sent out to 1,928,725 individuals and there were 94,373 positive FIT tests (in 92,848 individuals) during the study period. Before the pandemic, 60.7% participated in screening within 90 days. A minor reduction in participation was observed at the start of the pandemic (PR=0.95; 95% CI: 0.94-0.96 in pre-lockdown and PR=0.85; 95% CI: 0.85-0.86 in 1st lockdown) corresponding to a participation rate of 54.9% during pre-lockdown and 53.0% during 1st lockdown. This was followed by a 5-10% increased participation in screening corresponding to a participation rate of up to 64.9%. The largest increase in participation was observed among 55-59 year olds and among immigrants. The compliance with colonoscopy within 60 days was 89.9% before the pandemic. A slight reduction was observed during 1st lockdown (PR=0.96; 95% CI: 0.93-0.98), where after it resumed to normal levels.

    Conclusions: Participation in the Danish FIT-based colorectal cancer screening programme and subsequent compliance to colonoscopy after a positive FIT result was only slightly affected by the COVID-19 pandemic.

    Funding: The study was funded by the Danish Cancer Society Scientific Committee (grant number R321-A17417) and the Danish regions.

    1. Epidemiology and Global Health
    2. Medicine
    Nathan J Cheetham, Milla Kibble ... Claire J Steves
    Research Article

    Background: SARS-CoV-2 antibody levels can be used to assess humoral immune responses following SARS-CoV-2 infection or vaccination, and may predict risk of future infection. Higher levels of SARS-CoV-2 anti-Spike antibodies are known to be associated with increased protection against future SARS-CoV-2 infection. However, variation in antibody levels and risk factors for lower antibody levels following each round of SARS-CoV-2 vaccination have not been explored across a wide range of socio-demographic, SARS-CoV-2 infection and vaccination, and health factors within population-based cohorts.

    Methods: Samples were collected from 9,361 individuals from TwinsUK and ALSPAC UK population-based longitudinal studies and tested for SARS-CoV-2 antibodies. Cross-sectional sampling was undertaken jointly in April-May 2021 (TwinsUK, N = 4,256; ALSPAC, N = 4,622), and in TwinsUK only in November 2021-January 2022 (N = 3,575). Variation in antibody levels after first, second, and third SARS-CoV-2 vaccination with health, socio-demographic, SARS-CoV-2 infection and SARS-CoV-2 vaccination variables were analysed. Using multivariable logistic regression models, we tested associations between antibody levels following vaccination and: (1) SARS-CoV-2 infection following vaccination(s); (2) health, socio-demographic, SARS-CoV-2 infection and SARS-CoV-2 vaccination variables.

    Results: Within TwinsUK, single-vaccinated individuals with the lowest 20% of anti-Spike antibody levels at initial testing had 3-fold greater odds of SARS-CoV-2 infection over the next six to nine months (OR = 2.9, 95% CI: 1.4, 6.0), compared to the top 20%. In TwinsUK and ALSPAC, individuals identified as at increased risk of COVID-19 complication through the UK 'Shielded Patient List' had consistently greater odds (2- to 4-fold) of having antibody levels in the lowest 10%. Third vaccination increased absolute antibody levels for almost all individuals, and reduced relative disparities compared with earlier vaccinations.

    Conclusions: These findings quantify the association between antibody level and risk of subsequent infection, and support a policy of triple vaccination for the generation of protective antibodies.

    Funding: Antibody testing was funded by UK Health Security Agency. The National Core Studies program is funded by COVID-19 Longitudinal Health and Wellbeing - National Core Study (LHW-NCS) HMT/UKRI/MRC (MC_PC_20030 & MC_PC_20059). Related funding was also provided by the NIHR 606 (CONVALESCENCE grant COV-LT-0009). TwinsUK is funded by the Wellcome Trust, Medical Research Council, Versus Arthritis, European Union Horizon 2020, Chronic Disease Research Foundation (CDRF), Zoe Ltd and the National Institute for Health Research (NIHR) Clinical Research Network (CRN) and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC.